The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 05, 2009

Filed:

Jun. 11, 2002
Applicants:

Kyoji Yamaguchi, Saitama, JP;

Hisataka Yasuda, Tochigi, JP;

Nobuaki Nakagawa, Tochigi, JP;

Nobuyuki Shima, Tochigi, JP;

Masahiko Kinosaki, Tochigi, JP;

Eisuke Tsuda, Tochigi, JP;

Masaaki Goto, Tochigi, JP;

Kazuki Yano, Tochigi, JP;

Akihiro Tomoyasu, Tochigi, JP;

Fumie Kobayashi, Tochigi, JP;

Naohiro Washida, Tochigi, JP;

Ken Takahashi, Tochigi, JP;

Tomonori Morinaga, Tochigi, JP;

Kanji Higashio, Saitama, JP;

Inventors:

Kyoji Yamaguchi, Saitama, JP;

Hisataka Yasuda, Tochigi, JP;

Nobuaki Nakagawa, Tochigi, JP;

Nobuyuki Shima, Tochigi, JP;

Masahiko Kinosaki, Tochigi, JP;

Eisuke Tsuda, Tochigi, JP;

Masaaki Goto, Tochigi, JP;

Kazuki Yano, Tochigi, JP;

Akihiro Tomoyasu, Tochigi, JP;

Fumie Kobayashi, Tochigi, JP;

Naohiro Washida, Tochigi, JP;

Ken Takahashi, Tochigi, JP;

Tomonori Morinaga, Tochigi, JP;

Kanji Higashio, Saitama, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/18 (2006.01);
U.S. Cl.
CPC ...
Abstract

Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.


Find Patent Forward Citations

Loading…